Figure 6
Figure 6. Detection of miR-28 overexpression in platelets from MPN patients. (A) miR-28 relative levels are depicted in phe positive control that is represented by Mo7e cells transduced by the pMegix vector overexpressing miR-28 (± SD quantification done in triplicate). Ctrl indicates control platelets from healthy volunteers; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis. Status for JAK2 or MPL mutations is indicated under the histograms. (B) Relative miR-28 levels in control and MPN platelets. Mean miR-28 levels are represented on graphs (P = .014; Mann-Whitney test). Positive JAK2 V617F patients were grouped accordingly to their allele burden (< 50% or > 50% JAK2 V617F) and examined for miR-28 levels (P = .003; Mann-Whitney test). (C) miR-28 relative levels in platelets and granulocytes of the same patient. Patient numbers and normalization of relative miR-28 quantity are the same as in panel A.

Detection of miR-28 overexpression in platelets from MPN patients. (A) miR-28 relative levels are depicted in phe positive control that is represented by Mo7e cells transduced by the pMegix vector overexpressing miR-28 (± SD quantification done in triplicate). Ctrl indicates control platelets from healthy volunteers; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis. Status for JAK2 or MPL mutations is indicated under the histograms. (B) Relative miR-28 levels in control and MPN platelets. Mean miR-28 levels are represented on graphs (P = .014; Mann-Whitney test). Positive JAK2 V617F patients were grouped accordingly to their allele burden (< 50% or > 50% JAK2 V617F) and examined for miR-28 levels (P = .003; Mann-Whitney test). (C) miR-28 relative levels in platelets and granulocytes of the same patient. Patient numbers and normalization of relative miR-28 quantity are the same as in panel A.

Close Modal

or Create an Account

Close Modal
Close Modal